The use of i.v. IG therapy in dermatology (Q36986054)

17 August 2017

1 reference

title

The use of i.v. IG therapy in dermatology (English)

1 reference

17 August 2017

Anthony P Fernandez

1 reference

17 August 2017

Francisco A Kerdel

series ordinal

1 reference

17 August 2017

language of work or name

1 reference

1 July 2007

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

288-305

1 reference

Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Fibrosis regression induced by intravenous gammaglobulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

A systematic review of treatments for bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

How genetic defects are identified

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Bullous diseases in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Treatment of Bullous Pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Bullous Pemphigoid Responding to Sulfapyridine and the Sulfones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Toxic epidermal necrolysis: does immunoglobulin make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Stevens-Johnson syndrome developing in a girl with systemic lupus erythematosus on high-dose corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Transient and partial effect of high-dose intravenous immunoglobulin in polyarteritis nodosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin therapy for resistant ocular Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Pathophysiology of chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Mechanisms of autoimmune activation of basophils in chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin therapy suppresses manifestations of the angioedema with hypereosinophilia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Clinical usefulness of intravenous human immunoglobulins in invasive group A Streptococcal infections: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Psoriasis: response to high-dose intravenous immunoglobulin in three patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulins control scleromyxoedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Anticonvulsant hypersensitivity syndrome: treatment with corticosteroids and intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Polymorphic light eruption occurring in common variable hypogammaglobulinaemia, and resolving with intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Thrombotic complications after intravenous immunoglobulin therapy in two patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Safety considerations in IGIV utilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Immunoglobulin therapy: history, indications, and routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-? present in serum from patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1529-8019.2007.00142.X

10.1111/J.1529-8019.2007.00142.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference